-62%

est. 2Y upside i

HealthcareSeries B

Rank

#1656

Sector

HealthTech

Est. Liquidity

~3Y

Data Quality

Data: Medium

Vista AI presents a moderate upside opportunity for a job seeker, with an estimated 52.5% expected return over a two-year horizon.

Last updated: March 10, 2026

Bull (30%)+200%

Vista AI successfully expands its FDA-cleared platform beyond cardiac MRI into brain, prostate, and spine, capturing significant market share in automated MRI scanning. Strategic partnerships with health systems drive rapid adoption, pushing revenue to $100M+ by 2028 and justifying a $540M valuation, a 3x multiple on its current estimated valuation.

Base (35%)+50%

Vista AI continues to grow steadily within its niche, expanding its cardiac MRI platform and achieving moderate success in new anatomies. It maintains its competitive position against smaller AI imaging firms but faces increasing pressure from incumbent medical imaging manufacturers, leading to a $270M valuation, a 1.5x return on current equity.

Bear (35%)-50%

Large incumbents like Siemens, GE, or Philips acquire or develop superior AI automation solutions, commoditizing Vista AI's offerings. Regulatory hurdles for new anatomies prove more challenging than expected, slowing expansion. This leads to a down round or acquisition at a reduced valuation of $90M, wiping out a significant portion of common stock value due to liquidation preferences.

Est. time to liquidity~3.0 years

Preference Stack Risk

high

Investors hold $38.2M in liquidation preferences ahead of common stock, representing 21.2% of the estimated $180M post-money valuation.

Dilution Risk

moderate

As a Series B company, Vista AI will likely require at least one to two more funding rounds, leading to further dilution for existing equity holders.

Secondary Liquidity

none

There is no indication of active secondary markets or tender offers for Vista AI's equity at this stage.

Questions to Ask at the Interview

Strategic questions based on Vista's data — designed to show you've done your homework.

  • 1

    “Given the strong strategic backing from health systems in your Series B, how do you plan to leverage these partnerships to accelerate adoption and defend against potential competitive moves from major imaging equipment manufacturers like GE Healthcare or Siemens Healthineers?”

  • 2

    “With a TAM of $193B and SAM of $38.6B, what are the key milestones and growth levers Vista AI is focusing on to achieve significant market penetration beyond its initial cardiac MRI platform, particularly in terms of revenue scale and customer acquisition over the next 2-3 years?”

  • 3

    “Considering the Series B funding and the typical venture capital lifecycle, what is the company's anticipated timeline and strategy for a liquidity event (e.g., IPO or acquisition) for employees, and how does the current preference stack impact potential common stock returns?”

Community

Valuation Sentiment

Our model estimates -62% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.